This case-control study aims to investigate the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets. The project will involve drug repurposing using Mendelian Randomization, a smoking cessation intervention, and the analysis of methylation status in participants undergoing nicotine withdrawal.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Novel druggable gene targets for smoking cessation
Timeframe: Upon completion of Mendelian randomization analysis
Association between methylation of candidate genes and nicotine dependence scores
Timeframe: Baseline
Association between DNA methylation of candidate drug target genes and motivation to quit smoking scores
Timeframe: 3 and 6 months post nicotine cessation
Association between methylation and smoking relapse vulnerability
Timeframe: 3 and 6 months post nicotine cessation